Navigation Links
Dr. Daniel Von Hoff Joins Lixte Biotechnology's Scientific Advisory Board
Date:1/7/2014

EAST SETAUKET, N.Y., Jan. 7, 2014 /PRNewswire/ -- John S. Kovach, M.D., President and CEO, Lixte Biotechnology Holdings, Inc. (LIXT.PK), announces the appointment of Daniel D. Von Hoff, MD, FACP, to the company's Scientific Advisory Board.

"We are extremely pleased that Dr. Von Hoff has joined the Lixte Scientific Advisory Board.  Dr. Von Hoff is internationally recognized as a leader in the pre-clinical and clinical development of new anti-cancer drugs.  He and his colleagues were instrumental in the advancement of many anti-cancer drugs now used routinely in cancer care.  We very much look forward to Dr. Von Hoff's suggestions regarding the most efficient clinical development of our proprietary anti-cancer compounds," says Dr. Kovach.

Dr. Von Hoff is currently Physician in Chief, Distinguished Professor and Director of Clinical Translational Research Division at TGen (Translational Genomics Research Institute), Phoenix, AZ.  He is also Chief Scientific Officer for US Oncology and for Scottsdale Healthcare's Clinical Research Institute and holds an appointment as Professor of Medicine, Mayo Clinic, Scottsdale, AZ. 

Dr. Von Hoff served on the National Cancer Advisory Board from 2004-2010.  He is a past President of the American Association of Cancer Research (AACR), Fellow of the American College of Physicians (FACP), and a member and past board member of the American Society of Clinical Oncology (ASCO).  He is a founder of ILEX™Oncology, Inc., subsequently acquired by Genzyme.  Dr. Von Hoff is founder and the Editor Emeritus of Investigational New Drugs: The Journal of New Anti-Cancer Agents and Editor-in-Chief of Molecular Cancer Therapeutics

Dr. Von Hoff has published more than 600 papers and 135 book chapters.  He received the 2010 David A. Karnofsky Memorial Award from ASCO for his outstanding contributions to cancer research leading to significant improvement in patient care.

About Lixte Biotechnology Holdings, Inc.

Lixte is a drug discovery company, using biomarker technology to identify enzyme targets associated with serious common diseases and then design novel compounds to attack those targets. Lixte's product pipeline encompasses two major categories of compounds at various stages of pre-clinical and clinical development which the company believes have broad therapeutic potential not only for cancer but for other debilitating and life-threatening diseases. Lixte's unique phosphatase inhibitor, LB-100, is in a Phase I cancer trial at two NCI designated Comprehensive Cancer Centers (see ClinicalTrials.gov: Identifier NCTO1837667). For further discussion of the Lixte pipeline, go to: http://lixte.com/Nature_Biotechnology_2013_Lixte_Ad.pdf

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto in the Annual Report on Form 10Q for September 30, 2013.

For additional information, please see: www.lixte.com


'/>"/>
SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. GenoSpace Expands Its Management Team by Appointing Daniel Meyer as Chief Financial Officer
2. Bioentrepreneurship Leader Joins UM Ventures Team
3. Anthony A. Charity Joins Tunnell Consulting
4. CHI Joins More Than 30 State Life Sciences Associations in Urging Budget Conferees to Fix FDA User Fee Sequester
5. Craig Peloquin Joins Glissandra Skin Care as VP of Sales and Marketing
6. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
7. Dr. Ungerleider Joins Forces with Childhelp
8. ReachMD Radio Joins Clear Channel’s iHeartRadio
9. Soltex Consulting Joins Medidata Partner Program to Better Optimize Clinical Processes
10. Andrew Powell Joins InterMune As Executive Vice President And General Counsel
11. Green Dot Holdings LLC CEO, Mark Remmert, Joins Industry Thought Leaders to Discuss Holistic Sustainable Design at A Better World by Design Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... ... internist, who will review how testing for 1,25-Dihydroxyvitamin D can enhance clinical practice. ... 25-OH-vitamin D and 1,25 dihydroxyvitamin D. , Dr. Gregory Plotnikoff, senior consultant with ...
(Date:4/27/2017)... , April 27, 2017  Pendant Biosciences, Inc. ... innovative surface modification and drug delivery technologies, today announced ... Innovation, JLABS @ Toronto . ... Officer of Pendant Biosciences, noted, "We are excited to ... community, and are honored to be the ...
(Date:4/26/2017)... Centennial, CO (PRWEB) , ... April 25, 2017 , ... ... test offerings were added to its extensive test menu: Nucleic Acid Testing (NAT) ... that time, LABS was only able to offer NAT screening for blood donors under ...
(Date:4/25/2017)... ... ... As part of the Stago EdVantage Virtual University Virtual Event, ... order to illuminate this clinical problem for people unfamiliar with the topic. , DIC ... high degree of morbidity and mortality. DIC is a confusing disorder from both diagnostic ...
Breaking Biology Technology:
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
(Date:3/23/2017)... DUBLIN , Mar. 23, 2017 Research ... Anti-Theft System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 8.8% over the next ... This industry report analyzes the market estimates and forecasts for all ...
(Date:3/20/2017)... 2017 At this year,s CeBIT Chancellor Dr. ... DERMALOG. The Chancellor came to the DERMALOG stand together with the Japanese ... CeBIT partner country. At the largest German biometrics company the two government ... and iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
Breaking Biology News(10 mins):